Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris

Circulation

Volumn 110, Issue 13, 2004, Pages 1747-1753

  Zouridakis, Emmanouil ^a   Avanzas, Pablo ^b   Arroyo Espliguero, Ramón ^c   Fredericks, Salim ^a   Kaski, Juan Carlos ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

Author keywords

C reactive protein; Cell adhesion molecules; Coronary disease; Inflammation; Neopterin

Indexed keywords

BIOCHEMICAL MARKER; C REACTIVE PROTEIN; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; NEOPTERIN;

ADULT; AGED; ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; BLOOD LEVEL; CELL ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DISEASE COURSE; DISEASE MARKER; ENDOTHELIUM CELL; FEMALE; HUMAN; INFLAMMATION; MACROPHAGE ACTIVATION; MALE; PRIORITY JOURNAL; STABLE ANGINA PECTORIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANGINA PECTORIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COMORBIDITY; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; CORONARY RESTENOSIS; CORONARY STENOSIS; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; MACROPHAGE ACTIVATION; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPTERIN; RISK FACTORS; SOLUBILITY; VASCULAR CELL ADHESION MOLECULE-1;

EID: 4644337418     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000142664.18739.92     Document Type: Article

References (37)

1. Bruschke AV, Wijers TS, Kolsters W, et al. The anatomic evolution of coronary artery disease demonstrated by coronary arteriography in 256 nonoperated patients. Circulation. 1981;63:527-536.
2. Kaski JC, Chester MR, Chen L, et al. Rapid angiographic progression of coronary artery disease in patients with angina pectoris: the role of complex stenosis morphology. Circulation. 1995;92:2058-2065.
3. Kaski JC, Chen L, Chester M. Rapid angiographic progression of "target" and "nontarget" stenoses in patients awaiting coronary angioplasty. J Am Coll Cardiol. 1995;26:416-421.
4. Rioufol G, Finet G, Ginon I, et al. Multiple atherosclerotic plaque rupture in acute coronary syndrome: a three-vessel intravascular ultrasound study. Circulation. 2002;106:804-808.
5. Mann J, Davies MJ. Mechanisms of progression in native coronary artery disease: role of healed plaque disruption. Heart. 1999;82:265-268.
6. Arroyo-Espliguero R, Avanzas P, Cosin-Sales J, et al. C-reactive protein elevation and disease activity in patients with coronary artery disease. Eur Heart J. 2004;25:401-408.
7. Garcia-Moll X, Coccolo F, Cole D, et al. Serum neopterin and complex stenosis morphology in patients with unstable angina. J Am Coll Cardiol. 2000;35:956-962.
8. Avanzas P, Arroyo-Espliguero R, Cosín-Sales J, et al. Markers of inflammation and multiple complex stenoses (pancoronary plaque vulnerability) in patients with non-ST segment elevation acute coronary syndromes. Heart. 2004;90:847-852.
9. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
10. Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98:731-733.
11. Yeh ET, Anderson HV, Pasceri V, et al. C-reactive protein: linking inflammation to cardiovascular complications. Circulation. 2001;104:974-975.
12. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000;102:2165-2168.
13. Asakura M, Ueda Y, Yamaguchi O, et al. Extensive development of vulnerable plaques as a pan-coronary process in patients with myocardial infarction: an angioscopic study. J Am Coll Cardiol. 2001;37:1284-1288.
14. Goldstein JA, Demetriou D, Grines CL, et al. Multiple complex coronary plaques in patients with acute myocardial infarction. N Engl J Med. 2000;343:915-922.
15. Ridker PM, Hennekens CH, Roitman-Johnson B, et al. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet. 1998;351:88-92.
16. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res. 1995;77:863-868.
17. Braunwald E. Unstable angina: a classification. Circulation. 1989;80:410-414.
18. Zouridakis EG, Schwartzman R, Garcia-Moll X, et al. Increased plasma endothelin levels in angina patients with rapid coronary artery disease progression. Eur Heart J. 2001;22:1578-1584.
19. Moreno PR, Falk E, Palacios IF, et al. Macrophage infiltration in acute coronary syndromes: implications for plaque rupture. Circulation. 1994;90:775-778.
20. Burke AP, Tracy RP, Kolodgie F, et al. Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies. Circulation. 2002;105:2019-2023.
21. Poston RN, Haskard DO, Coucher JR, et al. Expression of intercellular adhesion molecule-1 in atherosclerotic plaques. Am J Pathol. 1992;140:665-673.
22. Hwang SJ, Ballantyne CM, Sharrett AR, et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation. 1997;96:4219-4225.
23. Pradhan AD, Rifai N, Ridker PM. Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men. Circulation. 2002;106:820-825.
24. Zairis MN, Ambrose JA, Manousakis SJ, et al. The impact of plasma levels of C-reactive protein, lipoprotein (a) and homocysteine on the long-term prognosis after successful coronary stenting: the Global Evaluation of New Events and Restenosis After Stent Implantation Study. J Am Coll Cardiol. 2002;40:1375-1382.
25. Chen L, Crook JR, Tousoulis D, et al. Complex stenosis morphology predicts late reocclusion during follow-up after myocardial infarction in patients with patent infarct-related coronary arteries. Am Heart J. 1998;136:877-883.
26. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 1995;91:2844-2850.
27. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem. 1999;274:21491-21494.
28. Huber C, Batchelor JR, Fuchs D, et al. Immune response-associated production of neopterin: release from macrophages primarily under control of interferon-gamma. J Exp Med. 1984;160:310-316.
29. Gupta S, Fredericks S, Schwartzman RA, et al. Serum neopterin in acute coronary syndromes. Lancet. 1997;349:1252-1253.
30. Garcia-Moll X, Cole D, Zouridakis E, et al. Increased serum neopterin: a marker of coronary artery disease activity in women. Heart. 2000;83:346-350.
31. Avanzas P, Arroyo-Espliguero R, Cosin-Sales J, et al. Prognostic value of neopterin levels in treated patients with hypertension and chest pain but without obstructive coronary artery disease. Am J Cardiol. 2004;93:627-629.
32. Kai H, Ikeda H, Yasukawa H, et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol. 1998;32:368-372.
33. Noji Y, Kajinami K, Kawashiri MA, et al. Circulating matrix metallo-proteinases and their inhibitors in premature coronary atherosclerosis. Clin Chem Lab Med. 2001;39:380-384.
34. Noji Y, Higashikata T, Inazu A, et al. Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia. Atherosclerosis. 2002;163:157-164.
35. van der Wal AC, Becker AE. Atherosclerotic plaque rupture: pathologic basis of plaque stability and instability. Cardiovasc Res. 1999;41:334-344.
36. Zairis M, Papadaki O, Manousakis S, et al. C-reactive protein and multiple complex coronary artery plaques in patients with primary unstable angina. Atherosclerosis. 2002;164:355-359.
37. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291:1071-1080.